ORCID ID

0000-0001-5604-721X

Publication Date

2019-06-05

Document Type

Doctoral Dissertation

Academic Program

Clinical and Population Health Research

Department

Population and Quantitative Health Sciences

First Thesis Advisor

Kate Lapane

Keywords

Anticoagulants, epidemiology, nursing home, older adults, comparative effectiveness, health outcomes

Abstract

Background

Fewer than one-third of nursing home residents with atrial fibrillation were treated with the only available oral anticoagulant, warfarin, historically. Management of atrial fibrillation has transformed in recent years with the approval of 4 direct-acting oral anticoagulants (DOACs) since 2010.

Methods

Using the national Minimum Data Set 3.0 linked to Medicare Part A and D claims, we first described contemporary (2011-2016) warfarin and DOAC utilization in the nursing home population (Aim 1). In Aim 2, we linked residents to nursing home and county level data to study associations between resident, facility, county, and state characteristics and anticoagulant treatment. Using a new-user active comparator design, we then compared the incidence of safety (i.e., bleeding), effectiveness (i.e., ischemic stroke), and mortality outcomes between residents initiating DOACs versus warfarin (Aim 3).

Results

The proportion of residents with atrial fibrillation receiving treatment increased from 42.3% in 2011 to 47.8% as of December 31, 2016, at which time 48.2% of treated residents received DOACs. Demographic and clinical characteristics of residents using DOACs and warfarin were similar in 2016. Half of the 8,734 DOAC users received standard dosages and most were treated with apixaban (54.4%) or rivaroxaban (35.8%) in 2016.

Compared with warfarin, bleeding rates were lower and ischemic stroke rates were higher for apixaban users. Ischemic stroke and bleeding rates for dabigatran and rivaroxaban were comparable to warfarin. Mortality rates were lower versus warfarin for each DOAC.

Conclusions

In nursing homes, DOACs are being used commonly and with equal or greater benefit than warfarin.

DOI

10.13028/tfcw-vx13

Rights and Permissions

Copyright is held by the author, with all rights reserved.

Download

Share

COinS